Leitliniengerechtes Management der Osteoporose

Schlüsselwörter

Osteoporose - DVO-Leitlinien - Diagnostik - Medikamente - Behandlungsstrategien - Monitoring

Key words

osteoporosis - guidelines - diagnosis - drugs - strategies of therapy - monitoring

Literatur

• 1 Bartl R. Osteoporose: Was ist gesichert in der Therapie?.  Internist. 2002;  43 1529-1543
• 2 Bartl R, Bartl C, Mutschler W. Diagnostik und Therapie der Osteoporose: Strategie für eine effiziente Prävention von Folgefrakturen.  Unfallchirurg. 2003;  106 526-541
• 3 Bischoff-Ferrari H. How to select the dosis of vitamin D in the managment of osteoporosis.  Osteoporos Int. 2007;  18 401-407
• 4 Black D. et al . Effects of continuing or stopping alendronate after 5 years of treatment. The Fracture Intervention Trial Long-term Extension (FLEX): A randomized Trial.  JAMA. 2006;  296 2927-2936
• 5 Burge R, Dawson-Hughes B, Solomon D. et al . Incidence and economic burden of osteoporostic-related fractures in the United States, 2005 - 2025.  J Bone Miner Res. 2007;  22 465-475
• 6 DaFonseca K, Baier M, Grafe I. et al . Ballonkyphoplastie in der Therapie der Wirbelkörperfrakturen.  Orthopäde. 2006;  35 1101-1110
• 7 Delmas P, Rizzoli R, Cooper C. Treatment of patients with postmenopausal osteoporosis is worthwile. The position of the International Osteoporosis Foundation.  Osteoporos Int. 2005;  16 1-5
• 8 Grady D. Postmenopausal hormones - therapy for symptoms only.  N Engl J Med. 2003;  348 1835-1837
• 9 Häuselmann H, Rizzoli R. A comprehensive review of treatments for postmenopausal osteoporosis.  Osteoporos Int. 2003;  14 2-12
• 10 Häussler B, Gothe H, Mangiapane S. et al . Versorgung von Osteoporose-Patienten in Deutschland. Ergebnisse der BoneEVA-Studie.  Dtsch Ärztebl. 2006;  39 B2199-2205
• 11 Johnell O, Oden A, De Laet C. et al . Biochemical markers and the assessment of fracture probability.  Osteoporos Int. 2002;  13 523-526
• 12 Marcus R, Wong M, Heath H. et al . Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint.  Endocrine Reviews. 2002;  23 16-37
• 13 Miller P, Zapalowski C, Kulak C. et al . Bone densitometry: the best way to detect osteoporosis and to monitor therapy.  J Clin Endocrinol Metab. 1999;  84 1867-1871
• 14 Minne H, Pfeifer M. Evidenzbasierte Therapie der Osteoporose.  Dtsch Med Wochenschr. 2003;  128 931-934
• 15 Pfeilschifter J. Postmenopausale und kortikoidinduzierte Osteoporose.  Internist. 2005;  46 S31-S37
• 16 Raisz L G. Screening of Osteoporosis.  N Engl J Med. 2005;  353 164-171
• 17 Reid I, Brown J, Burckhardt P. et al . Intravenous zoledronic acid in postmenopausal women with low bone mineral density.  N Engl J Med. 2002;  346 653-661
• 18 Rosen C. Postmenopausal osteoporosis.  N Engl J Med. 2005;  353 595-603
• 19 Sambrook P, Cooper C. Osteoporosis.  Lancet. 2006;  367 2010-2018
• 20 Siris E, Chen Y, Abbott T. et al . Bone mineral density thresholds for pharmacological intervention to prevent fractures.  Arch Intern Med. 2004;  164 1108-1112